Olema Pharmaceuticals (OLMA) Liabilities and Shareholders Equity (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $530.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 29.54% year-over-year to $530.6 million; the TTM figure through Mar 2026 stood at $1.8 billion (up 33.69% YoY), while the FY2025 annual figure was $533.4 million, up 18.28% from the prior year.
• Liabilities and Shareholders Equity retreated to $530.6 million in Q1 2026 per OLMA's latest filing, from $533.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $533.4 million in Q4 2025 and bottomed at $177.6 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $313.3 million across 5 years, with a median of $276.9 million in 2023.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity dropped 29.43% — and 2024, when it jumped 62.84%.
• Olema Pharmaceuticals' Liabilities and Shareholders Equity stood at $215.6 million in 2022, then rose by 28.43% to $276.9 million in 2023, then jumped by 62.84% to $451.0 million in 2024, then grew by 18.28% to $533.4 million in 2025, then slipped by 0.52% to $530.6 million in 2026.
• Business Quant data shows OLMA's Liabilities and Shareholders Equity at $530.6 million in Q1 2026, $533.4 million in Q4 2025, and $352.5 million in Q3 2025.